In the health sector, FDA has granted a de novo clearance to an artificial intelligence program capable of reading a standard brain MRI scan and predicting a patient’s chances of progressing from mild cognitive impairment and early memory loss to Alzheimer’s disease and dementia within five years.
Described as a virtual microscope, the BrainSee prognostic program could be implemented before a positron emission tomography (PET) scan, which requires injections of radioactive tracers, or instead of biopsies of cerebrospinal fluid.
The program only requires a common 3D MRI scan, with no contrast injections, as well as cognitive test scores that are typically collected during a diagnostic workup.
More details in the following link.
